← Russell 3000 cross-section

KRMD KORU Medical Systems, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$149m
Revenue TTM
$45m
Net income TTM
$-2m
Free cash flow
$1m
Composite score
Sector rank
#2967

Valuation

P / E
EV / EBITDA
EV / sales
3.1
FCF yield
0.52%
Earnings yield vs 10-yr
-5.94pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4.0%
EBITDA margin
-1.9%
ROE
-10.1%
ROIC
-16.9%
Revenue growth
22.4%

Insider activity, last 90 days

Net open-market
$0.05m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The Company ended the second quarter of 2026 with $12.0 million in net revenues, an 18.2% increase compared to $10.2 million in the same period last year. Revenues were driven by growth in our core domestic and international business of 12.4% and 59.1%, respectively, along with a decrease of 35% in our pharma services and clinical trials business. Gross profit for the second quarter of 2026 was $7.8 million, a 21.2% increase compared to $6.5 million in the same period last year. Gross margin was 65.1% for the three months ended June 30, 2026, an increase from 63.5% in the prior year period. …KORU Medical Systems, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →